About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
Strategic Alliances
  > ABOUT US
  Overview
  Businesses
  Key Facts
  Vision Mission Values
  People
  Quality
  CSR Policy
  EHS Policy
  History
  Awards
  Biocon in Malaysia
  
  
     
 

Biocon in Malaysia

Biocon Malaysia: Making Diabetes Care Affordable and Accessible

Biocon Sdn. Bhd. (Biocon Malaysia) has set up Asia’s largest integrated insulins manufacturing facility at the Biotech Park in Johor, Malaysia with an investment of about USD 275 million, which is the highest foreign investment in Malaysia’s biotech sector till date. Biocon Malaysia is the first overseas biopharma manufacturing and research facility of Biocon Ltd., Asia’s premier biopharmaceuticals company and employs a team of nearly 600 professionals at this state-of-the-art facility.

Biocon is working to address the large global unmet need for high quality, affordable biosimilar insulins that provide cost-effective alternatives to existing therapies. The company has given patients, physicians and payers a wider option of treatment choices, enhanced patient access to insulin and improved diabetes management. In doing so, Biocon has emerged among the Top 3 biosimilar players globally for insulins.

Biocon's Malaysia facility, which was commissioned in 2015, started commercial operations in 2017.

Biocon’s rh-insulin, manufactured at the Johor facility, is Malaysia’s first locally made biosimilar insulin to be approved by the National Pharmaceutical Regulatory Authority (NPRA) for commercial sales in the country. Biocon has also launched its biosimilar insulin glargine brand, Basalog®, in Malaysia.

By launching biosimilar Insugen® and Basalog®, Biocon is enabling access to safe, affordable and quality therapy options for the nearly 3.5 million people with diabetes in Malaysia.

In December 2016, Biocon Malaysia was awarded a MYR 300 million contract to be serviced over a period of three years for supplying rh-Insulin cartridges and re-usable insulin pens under the Malaysian government’s Off-Take Agreement (OTA) initiative, which seeks to encourage local manufacturing of new pharmaceutical products thus lowering the country’s reliance on imports and also enhancing the exports potential. In Malaysia, Biocon is distributing its insulin and insulin delivery devices through CCM Pharmaceuticals, a leading pharmaceutical player, which has an extensive supply chain network to service primary healthcare clinics and hospitals.

Biocon Malaysia is also making a significant contribution to build the biotechnology industry ecosystem in Malaysia. Senior leaders from Biocon Malaysia have joined the industry-academia panels of select Malaysian universities to enhance industry-academia collaborations and curriculum development. Biocon Malaysia is a great destination for the biotech professionals, both local and returning Malaysians. The company’s supply chain system embraces local biotech-enabling vendors and ancillary businesses, thus encouraging the development of a sustainable biotech eco-system in Malaysia.

Malaysia Unit Walkthrough


Contact:


Biocon Sdn. Bhd.,
No. 1, Jalan Bioteknologi 1,
Kawasan Perindustrian SiLC,
79200 Iskandar Puteri, Johor,
Malaysia

T +607-5600000
E: [email protected]

For Job Opportunities at Biocon Malaysia
write to [email protected]

 
 
Business Alliance
 
 
 
 
    
 
 Biocon Malaysia On
/bioconmalaysia
/bioconmalaysia

 

     
  Biocon

Businesses

Recommended sites Biocon on  
  Home
About Us

Investor Relations
Media Relations
Careers
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Biopharmaceuticals
Research Services
Active Discovery Program

ABLE
Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
       
  Report adverse event/side effects and product complaints    
       
  * Disclaimer            © 2016, Biocon. All Rights Reserved